FindTrial
Sign In

The Remnant Liver-First Strategy for Liver Autotransplantation in Patients with End-Stage Hepatic Alveolar Echinococcosis: A Pilot Study

The Remnant Liver-First Strategy for Liver Autotransplantation in Patients with End-Stage Hepatic Alveolar Echinococcosis: A Pilot Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300067330
Enrollment
Unknown
Registered
2023-01-04
Start date
2023-01-10
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-Stage Hepatic Alveolar Echinococcosis

Interventions

None listed

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Comprehensively evaluate patients with end-stage HAE who cannot be resectable by traditional liver resection combined with in vivo vascular reconstruction; 2. The general condition of the patient is good, and the liver function is ChildA/B; 3. The lesion invades the retrohepatic inferior vena cava and more than two hepatic veins; 4. The lesion invades grade 2 or grade 3 portal vein and hepatic artery; 5. Preoperative serum bilirubin = 0.35; 7. The lesion is located in the right hemi-liver; 8. Use enough space to place vascular occlusion bands or clamps during the operation.

Exclusion criteria

Exclusion criteria: 1. Extrahepatic lesions cannot be surgically removed; 2. The lesion can be effectively controlled after albendazole treatment.

Design outcomes

Primary

MeasureTime frame
Total survival rate;Incidence of complications;—

Countries

China

Contacts

Public ContactJiayin Yang

West China Hospital of Sichuan University

doctoryjy@scu.edu.cn+86 18980602047

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026